SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. (CRML) is trending with immense community interest due to escalating geopolitical discussions surrounding the United States' strategic interest in acquiring Greenland, which hosts CRML's significant Tanbreez rare earth project. Investors are actively discussing the potential for government involvement to secure critical rare earth supplies, driving substantial trading volume and speculation about a significant price surge. This heightened conversation reflects a broader market focus on establishing Western independence in the crucial rare earth sector.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy (MSTR) is trending sharply higher after MSCI announced it will not exclude Digital Asset Treasury Companies from its global indexes, reversing earlier plans. The community is buzzing with excitement, anticipating a significant short squeeze and a "path back to normalcy" following previous delisting fears. This decision removes a major overhang, fueling discussions of a substantial rally despite some lingering caution regarding Bitcoin's volatility.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing an explosive rally driven by intense demand for memory and storage within the rapidly expanding AI infrastructure sector, with community discussion highlighting widespread memory shortages and the stock's parabolic ascent. This significant price surge and high trading volume have ignited active debate among investors regarding the sustainability of the 'AI supercycle' and its valuation.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending amidst anticipation surrounding its Northern Data acquisition, which is expected to expand its cloud and GPU capabilities, potentially securing government contracts. Major investor Tether is also committing substantial funds for advertising and cloud services, coinciding with high community chatter about a looming short squeeze driven by significant short interest and the upcoming Rumble Wallet with crypto payment options.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is trending due to significant volatility following analyst downgrades from competitor banks, which many in the community perceive as market manipulation designed to acquire shares at a lower price. This sentiment is fueled by the recent completion of a public offering where underwriters exercised options to buy shares. Despite the sharp dip, long-term investors are actively 'buying the dip,' anticipating strong upcoming earnings and potential S&P 500 inclusion.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as community discussions highlight a perceived liquidity shortage and its appeal as a faster, lower-fee alternative to Bitcoin during network congestion. Traders are closely watching key resistance levels, anticipating a significant price breakout driven by these factors and ongoing developments in interoperability.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy (IMSR) is seeing renewed market interest after executing an agreement with the U.S. Department of Energy for Project TETRA, aiming to advance its Integral Molten Salt Reactor (IMSR) plant development. This news has ignited community discussion comparing its potential to sector peers like OKLO, emphasizing its role in the advanced nuclear era and the growing demand for clean energy, especially for AI infrastructure.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is actively trending as investors eagerly await its upcoming earnings report, with community speculation high regarding accelerated AI infrastructure demand and potential for new hyperscaler contracts to drive significant growth. Despite some caution around a transitional quarter impacting headline earnings, the focus remains on long-term guidance, cash flow, and the company's position to capitalize on the crucial data center bottleneck for high-performance computing. The notable short interest is also fueling discussions of a potential squeeze, adding to the bullish sentiment.

Momentus, Inc. engages in the provision of in-space infrastructure services. It offers space transportation and in-orbit servicing. The company was founded by Mikhail Kokorich in 2017 and is headquartered in Santa Jose, CA.

Momentus Inc - Ordinary Shares - Class A

Momentus Inc. is generating significant buzz following news of its innovative 3D-printed fuel tank technology and upcoming flight test, a development seen as a major step in advancing space transportation. The community is actively discussing the company's place within the burgeoning aerospace sector, with many anticipating substantial growth given its relatively small market valuation. High short interest and notable borrowing fees are also fueling expectations for increased price volatility.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending amidst heightened activity in the GLP-1 market, with upcoming J.P. Morgan conference participation and recent headlines about Novo Nordisk's oral Wegovy launching at aggressive pricing fueling community debate. Bulls strongly believe VKTX's VK2735, a dual GLP-1/GIP agonist with promising oral and injectable data, is significantly undervalued and poised for a major acquisition or substantial growth, while bears criticize management's perceived reluctance to secure a buyout and worry about escalating competition. The core tension centers on whether Viking can successfully navigate the rapidly evolving obesity and MASH landscape as an independent entity or if a strategic partnership or acquisition is inevitable, with the community actively discussing potential catalysts like regulatory feedback on oral VK2735's Phase 3 path.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 8.9% - Here's What Happened

Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 8.9% - Here's What Happened...

<ul><li>According to Telomir, more than 60,000 new cases of Leukemia are diagnosed each year in the U.S.</li><li>Leukemia cells rely heavily on iron as a fuel source, and Telomir-1 in previous research demonstrated the ability to reduce intracellular iron levels.&nbsp;</li><li>The new findings expand on the experimental drug’s previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models.</li></ul>Telomir Pharmaceuticals, Inc. (TELO) said on Friday that its investigational compound Telomir-1 killed aggressive human leukemia (HL60) cells in an in-vitro study.HL60 leukemia cells were treated with Telomir-1, which produced a clear, dose-dependent reduction in viable leukemia cells, indicating strong activity, the company said.Leukemia is a cancer of the blood and bone marrow defined by the uncontrolled growth of abnormal white blood cells.<a href="https://stocktwits.com/symbol/TELO">TELO shares</a> rose 8% at the time of writing.<h2 class="st-heading-2">New Findings</h2>According to Telomir, more than 60,000 new cases of Leukemia are diagnosed each year in the U.S. Leukemia cells rely heavily on iron as a fuel source, and Telomir-1 in previous research demonstrated the ability to reduce intracellular iron levels."The potency observed in HL60 leukemia cells is consistent with the broader biological patterns we have seen throughout Telomir's research…These findings support our scientific framework for evaluating Telomir-1 and inform the ongoing advancement of our overall oncology research program," the company’s chief scientific advisor, Itzchak Angel,<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://telomirpharma.com/#"> said</a>.The new findings expand on the experimental drug’s previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models. The compound is the company’s lead candidate.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TELO jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume levels rose from ‘extremely low’ to ‘high’ levels.TELO stock is down 66% this year and by 69% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/google-ai-infra-chief-must-double-ai-compute-twice-a-year/cLPMFWiREOK">Google AI Infra Chief Says It Must Double AI Compute Twice A Year To Meet Demand: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Telomir Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TELO Stock Jumps Pre-market After Early Study Results Show Leukemia Cell Death 

HL60 leukemia cells were treated with Telomir-1, which produced a clear, dose-dependent reduction in viable leukemia cells, indicating strong activity, the company said.

Equity

HL60 leukemia cells were treated with Telomir-1, which produced a clear, dose-dependent reduction in viable leukemia cells, indicating strong activity, the company said.


Shares of Telomir Pharmaceuticals surged nearly 40% in premarket trading on Thursday after the company announced promising new lab results showing that its experimental compound, Telomir-1, can selectively destroy triple-negative breast cancer cells.In laboratory studies using human triple-negative breast cancer (TNBC) cells, researchers observed that as Telomir-1 concentrations increased, more cancer cells stopped growing and eventually died. When iron was reintroduced into the system, the cells regained their ability to survive, pointing to a finding that confirmed Telomir-1’s effects are tied to iron regulation and cellular energy balance.The discovery is significant as TNBC cells are highly dependent on iron to fuel their rapid growth and spread. By cutting off that iron-driven metabolism, Telomir-1 appears to exploit a key vulnerability in these tumors, while normal cells, which process iron differently, remain largely unaffected.Telomir-1 has previously&nbsp;demonstrated the ability to reset abnormal DNA methylation patterns, which are chemical modifications that can alter gene function in preclinical models of cancer and age-related diseases.&nbsp;In this latest study, researchers believe its impact on energy and iron metabolism may stem from its influence on certain enzymes, known as Jumonji domain histone demethylases, which are known to drive tumor aggressiveness and treatment resistance.The study suggests that Telomir-1 may help restore the body’s natural balance, reactivating the normal genetic controls that cancer cells&nbsp;typically shut down to maintain growth.Telomir said it will now seek to use the drug in other hard-to-treat cancers, such as pancreatic and blood cancers, based on these results. The company also expects to soon begin animal studies, a crucial step in the process of seeking FDA approval to begin human trials.On Stocktwits, retail sentiment for Telomir was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said they were surprised the stock hadn’t “gone nuclear” after the breast cancer news broke, adding that they expect it to “go parabolic” in the next session.<stembedurl>https://stocktwits.com/DadiscplinedTrader/message/631612120</stembedurl>Another user commented that the company could eventually attract a buyout offer from a larger pharmaceutical player, suggesting the stock might rise ten to fifteen times, comparing it to past biotech acquisition successes, including that of Provention Bio by Sanofi.<stembedurl>https://stocktwits.com/MarketAttack/message/631581755</stembedurl><a href="https://stocktwits.com/symbol/TELO">Telomir’s stock</a> has declined 60% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Telomir’s stock (TELO) has declined 60% so far in 2025. | Image source: Getty Images

Why Telomir Pharmaceuticals Stock Is Rising 40% Premarket Today

The company said that its experimental drug, Telomir-1, selectively kills aggressive triple-negative breast cancer cells by disrupting their iron-based energy systems.

Shares of Telomir Pharmaceuticals surged during after-hours trading Thursday following the announcement of early laboratory data from research conducted on progeria-affected cells from a young patient.The stock closed at $1.21 on Thursday, then surged 138.8% after hours to $2.89 following the preclinical data.The rare disease, Hutchinson-Gilford Progeria Syndrome (HGPS), emerges from one gene mutation which triggers the accumulation of progerin within the body. The disease affects fewer than 30 children in the U.S.Most start showing symptoms like growth delays and heart problems by age two, and many don’t live past their early teens.&nbsp;The only approved drug, Zokinvy, can add a few years to their lives but doesn’t stop the damage or undo what’s already happened.In the new study, conducted by Smart Assays using cells provided by the Progeria Research Foundation, Telomir-1 improved cell survival in a dose-dependent manner, even under stress conditions.&nbsp;It also reduced levels of reactive oxygen species, a marker of oxidative damage, and corrected iron-induced calcium overload linked to mitochondrial dysfunction.The company stated that these results, observed in actual patient-derived cells, demonstrate that Telomir-1 not only protects cells but also restores critical biological functions.&nbsp;Telomir-1 is designed to regulate metal ions, reduce oxidative stress, restore mitochondrial health, extend telomeres, reverse muscle loss, and reset age-related DNA methylation patterns.CEO Erez Aminov said that the findings support broader potential beyond progeria, including neurodegeneration and metabolic disorders.The results also validated prior preclinical work in animal models, where Telomir-1 extended lifespan and reversed age phenotypes in zebrafish and C. elegans models of Werner syndrome, an adult form of progeria.&nbsp;Telomir is completing IND-enabling studies and is due to meet with the U.S. Food and Drug Administration (FDA) to discuss potential regulatory pathways, including orphan drug designation.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.The Telomir stream on Stocktwits saw a nearly 30% increase in watcher count over the past 24 hours, leading up to late Thursday, with the 24-hour message volume surging up by 8,600%.One user predicted a sharp move, saying Telomir could hit $8–$10 in post-market trading before “a crazy rocket” at the open toward $20 or higher.&nbsp;<stembedurl>https://stocktwits.com/time4themoon/message/621444979</stembedurl>Another user noted the stock’s momentum late in the session, and added that it was “seeing a nice bid going into the extended session close” with expectations to be “jamming in premarket.”<stembedurl>https://stocktwits.com/phijammaslamma/message/621430208</stembedurl><a href="https://stocktwits.com/symbol/TELO">Telomir’s stock</a> has declined 70.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Telomir Pharmaceuticals (TELO) said early lab results showed its drug candidate helped restore damaged cells from a child with progeria. (Photo credit: Getty Images)

Telomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage In Progeria Cells; Retail Eyes Bigger Gains

The early lab study used cells from a child with progeria and showed improvements in cell survival, reduced oxidative stress, and restored mitochondrial function, which are key signs of aging. 

Telomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage in Progeria Cells; Retail Eyes Bigger Gains

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company, which focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The firm’s initial focus on treatments to inhibit the production of pro-inflammatory cytokines, such as IL-17, by oral administration of TELOMIR-1 as a therapeutic treatment for stem cells in situ. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The company was founded by Christopher C. Chapman Jr. on August 26, 2021 and is headquartered in Miami, FL.

Telomir Pharmaceuticals Inc

Physical AI Infrastructure

Power & Energy to Support Growth

Healthcare Value & Innovation

Other – Comment Below

As markets head into 2026, investors are debating whether the next phase favors speculation or real-world execution. With capital rotating toward infrastructure, energy, and undervalued sectors like healthcare, which area do you think will matter most for portfolios in the year ahead?

Which Theme Will Matter Most for Portfolios in 2026?

Current Price	$1.45
Prev Close	$1.49
Open	$1.47
Dividend Yield	0.00%
50-Day Moving Average	$1.40
Beta	0.97
Avg. Volume	240,709.45
PE Ratio	-3.88

52-Week High	$5.40
52-Week Low	$1.12
Market Capitalization	$51.23M
EPS (Annual)	-$0.5597
Price to Book	7.03
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

TELO
Telomir Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest TELO News

TELOTelomir Pharmaceuticals Inc